ULTOMIRIS Emerging Drug Insight

“ULTOMIRIS Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about ULTOMIRIS for dermatomyositis in the seven major markets. A detailed picture of the ULTOMIRIS for dermatomyositis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the ULTOMIRIS for dermatomyositis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ULTOMIRIS market forecast analysis for dermatomyositis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in dermatomyositis.

Drug Summary

ULTOMIRIS (ravulizumab), the first and only long-acting C5 complement inhibitor, offers immediate, complete, and sustained complement inhibition. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body’s immune system. When activated uncontrolled, the complement cascade over-responds, leading the body to attack its healthy cells. ULTOMIRIS is administered intravenously every 8 weeks in adult patients, following a loading dose.

The company is actively recruiting for its registration Phase II/III study, which started in December 2021 and is expected to be completed by November 2024.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ULTOMIRIS description, mechanism of action, dosage and administration, research and development activities in dermatomyositis.
• Elaborated details on ULTOMIRIS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ULTOMIRIS research and development activities in dermatomyositis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ULTOMIRIS.
• The report contains forecasted sales of ULTOMIRIS for dermatomyositis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for dermatomyositis.
• The report also features the SWOT analysis with analyst views for ULTOMIRIS in dermatomyositis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ULTOMIRIS Analytical Perspective by DelveInsight

• In-depth ULTOMIRIS Market Assessment

This report provides a detailed market assessment of ULTOMIRIS for dermatomyositis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• ULTOMIRIS Clinical Assessment

The report provides the clinical trials information of ULTOMIRIS for dermatomyositis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for dermatomyositis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ULTOMIRIS dominance.
• Other emerging products for dermatomyositis are expected to give tough market competition to ULTOMIRIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ULTOMIRIS in dermatomyositis.
• Our in-depth analysis of the forecasted sales data of ULTOMIRIS from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ULTOMIRIS in dermatomyositis.

Key Questions

• What is the product type, route of administration and mechanism of action of ULTOMIRIS?
• What is the clinical trial status of the study related to ULTOMIRIS in dermatomyositis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ULTOMIRIS development?
• What are the key designations that have been granted to ULTOMIRIS for dermatomyositis?
• What is the forecasted market scenario of ULTOMIRIS for dermatomyositis?
• What are the forecasted sales of ULTOMIRIS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ULTOMIRIS for dermatomyositis?
• Which are the late-stage emerging therapies under development for the treatment of dermatomyositis?